Tirofiban drug class?

What class of drug is tirofiban?

Tirofiban is an antiplatelet medicine in the glycoprotein (GP) IIb/IIIa inhibitor class. It works by blocking the GP IIb/IIIa receptor on platelets, which reduces platelet aggregation and helps lower the risk of clot-related events. [1]

How does tirofiban work compared with other antiplatelet drugs?

Tirofiban directly inhibits platelet aggregation through GP IIb/IIIa blockade. That differentiates it from drugs that target other pathways, such as:
- Aspirin (COX-1 inhibition)
- P2Y12 inhibitors like clopidogrel/ticagrelor (ADP receptor inhibition)

Because tirofiban’s target is GP IIb/IIIa, it’s considered a “platelet aggregation inhibitor” specifically aimed at the final common pathway of aggregation. [1]

What kinds of conditions is this drug class used for?

GP IIb/IIIa inhibitors like tirofiban are used in settings where clinicians want rapid, potent antiplatelet effect, such as acute coronary syndromes and during certain cardiac procedures where preventing platelet-driven thrombosis is a goal. [1]

How is tirofiban different from heparin or thrombolytics?

• Tirofiban: antiplatelet effect (blocks platelet aggregation via GP IIb/IIIa). [1]
  
• Heparin: anticoagulant effect (affects clotting factors, not platelet aggregation primarily).
  
• Thrombolytics (e.g., alteplase): dissolves existing clots rather than preventing platelet aggregation.
  
  So tirofiban is aimed at platelet clot formation rather than dissolving an established thrombus or inhibiting clotting factors. [1]
  
  

Sources

1. https://www.drugs.com/tirofiban.html